Arrowhead Pharmaceuticals
CompanyUnited StatesFounded 1989
Arrowhead Pharmaceuticals develops 3 assets, the furthest in phase 3 (plozasiran in hypertriglyceridemia). Mostly oligonucleotide acting on lipid and ceramide metabolism, APOC3 and INHBE; based in the United States, founded in 1989.
- 3
- Assets
- Furthest stage
- Phase 3
- 9
- Trials
- 4
- Signals
Pipeline
3Silences hepatic APOC3 expression through RNA interference to lower triglyceride levels.
Phase 3, Oligonucleotide, Lipid and ceramide metabolism, APOC3, hypertriglyceridemia, severe hypertriglyceridemia
RNA interference targeting INHBE to reduce hepatic fat and improve metabolic function
Phase 2, Oligonucleotide, Lipid and ceramide metabolism, INHBE, metabolic dysfunction-associated steatohepatitis
Designed to lower low-density lipoprotein cholesterol and triglycerides.
Phase 1, Oligonucleotide, Lipid and ceramide metabolism, hyperlipidemia; mixed
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials9
- Signals8
- Similar companies6